Literature DB >> 3929380

Transfectomas provide novel chimeric antibodies.

S L Morrison.   

Abstract

Methods have been developed to transfect immunoglobulin genes into lymphoid cells. The transfected genes are faithfully expressed, and assembly can occur both between the transfected and endogenous chains and between two transfected chains. Gene transfection can be used to reconstitute immunoglobulin molecules and to produce novel immunoglobulin molecules. These novel molecules can represent unique combinations of heavy and light chains; alternatively, by means of recombinant DNA technology, genes can be assembled in vitro, transfected, and expressed. The end products of such manipulations include chimeric molecules with variable regions joined to different isotypic constant regions; this is possible both within and between species. It is also possible to synthesize altered immunoglobulin molecules, as well as molecules having immunoglobulin sequences fused with nonimmunoglobulin sequences (for example, enzyme sequences).

Mesh:

Substances:

Year:  1985        PMID: 3929380     DOI: 10.1126/science.3929380

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  25 in total

1.  Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody.

Authors:  M B Khazaeli; M N Saleh; T Liu; P M Kaladas; S C Gilman; A F LoBuglio
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

Review 2.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

3.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

Review 5.  Immunoconjugates: applications in targeted drug delivery for cancer therapy.

Authors:  B P Ram; P Tyle
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

Review 6.  Immunotherapy in the poisoned patient. Overview of present applications and future trends.

Authors:  J B Sullivan
Journal:  Med Toxicol       Date:  1986 Jan-Feb

7.  Differential effects of a murine and chimeric mouse/human anti-interleukin-2 receptor antibody on human T-cell proliferation.

Authors:  B Rose; A Gillespie; D Wunderlich; K Kelley; J Dzuiba; D Shedd; K Cahill; B Zerler
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

8.  Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.

Authors:  J M Trang; A F LoBuglio; R H Wheeler; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

9.  Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.

Authors:  E Oosterwijk; F M Debruyne
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

10.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Authors:  A F LoBuglio; R H Wheeler; J Trang; A Haynes; K Rogers; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.